Satellite Symposia Programme

13:45 - 14:45 
Childhood cancer survivors: endocrine late effects and management of growth hormone deficiency
Novo Nordisk
Hall A
Chair: Michel Polak (France)
13:45
Hall A
Session starts at 13:45
SAT1.1
Opening remarks
Michel Polak (France)

13:50
Hall A
Session starts at 13:45
SAT1.2
Childhood cancer treatments and associated endocrine late effects

14:10
Hall A
Session starts at 13:45
SAT1.3
How best to treat a childhood cancer survivor with growth hormone deficiency
Lars Sävendahl (Sweden)

14:30
Hall A
Session starts at 13:45
SAT1.4
Panel discussion
All

13:45 - 14:45 
Clinical Study of Pegylated Long-acting Growth Hormone in Children with Growth Hormone Deficiency
GeneScience Pharmaceuticals Co., Ltd. (GenSci)
Hall B
Chair: Bradley S Miller (USA)
13:45
Hall B
Session starts at 13:45
SAT2.1
Clinical Study of Pegylated Long-acting Growth Hormone in Children with Growth Hormone Deficiency
Xiaoping Luo (China)

18:30 - 20:00 
Management of paediatric short stature patients - looking to the future
Pfizer
Hall A
Chair: Marie-José Walenkamp (Netherlands)
18:30
Hall A
Session starts at 18:30
SAT3.1
Opening Remarks
Marie-José Walenkamp (Netherlands)

18:35
Hall A
Session starts at 18:30
SATd3
DEBATE: Patients with paediatric short stature should undergo genetic screening

18:35
Hall A
Session starts at 18:30
SATd3.1
DEBATE: Pro - "Molecular diagnosis is beneficial for short stature patients"

18:50
Hall A
Session starts at 18:30
SATd3.1
DEBATE: Against - "Molecular diagnosis is of no benefit for the vast majority of short stature patients"
Lars Sävendahl (Sweden)

19:05
Hall A
Session starts at 18:30
SAT3.4
Q&A and voting
Marie-José Walenkamp (Netherlands)

19:15
Hall A
Session starts at 18:30
SAT3.5
Short stature diagnosis and management: Key insights from the 2019 GRS Consensus Group

19:35
Hall A
Session starts at 18:30
SAT3.6
Emerging diagnostic tools and therapies for short stature

19:55
Hall A
Session starts at 18:30
SAT3.7
Q&A and meeting close
All

18:30 - 20:00 
Starting puberty at the right time: Optimising treatment to deliver long-term outcomes for patients with CPP
Ipsen
Hall C
Chair: Jean-Claude Carel (France)
18:30
Hall C
Session starts at 18:30
SAT4.1
Chairperson’s welcome and introduction

18:35
Hall C
Session starts at 18:30
SAT4.2
Improving CPP management: The insights and challenges of developing a national registry
Catarina Limbert (Portugal)

18:55
Hall C
Session starts at 18:30
SAT4.3
Flexible treatment options: what a 6 month formulation means for patients with CPP
Karen Klein (USA)

19:15
Hall C
Session starts at 18:30
SAT4.4
Long term outcomes with GnRHa: Treating patients with CPP
Liat de Vries (Israel)

19:35
Hall C
Session starts at 18:30
SAT4.5
Moving Forward Together

18:30 - 20:00 
Human and ehealth partnership for effective management of growth disorders
Merck
Hall B
Chair: Martin Savage (UK)
18:30
Hall B
Session starts at 18:30
SAT5.1
Gaps in the effective management of growth disorders
Tilman Rohrer (Germany)

19:00
Hall B
Session starts at 18:30
SAT5.2
Evidence-based eHealth tools

19:30
Hall B
Session starts at 18:30
SAT5.3
Understanding non-adherance to design personalised interventions